Arrowhead Pharmaceuticals  

177 East Colorado Boulevard, Ste 700
Pasadena,  CA  91105

United States
http://www.arrowheadpharma.com

• Booth: 3041

Arrowhead Pharmaceuticals develops innovative RNAi-based therapeutics to treat diseases by silencing causative genes. Arrowhead is committed to advancing cardiometabolic research for patients who have diseases with significant unmet needs.

 Press Releases

• Patient Resource Hub (Mar 24, 2025)

  Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

• Arrowhead Disease State Education Campaign Launch (Mar 24, 2025)

  Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by FCS

• Arrowhead Pharmaceuticals NDA Filing Acceptance (Mar 24, 2025)

  Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

• Arrowhead Pharmaceuticals Pipeline (Mar 24, 2025)

  Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases